Amy Smith, APRN
Family · Southbury, CTNPI 1750617817
Payments from drug & device makers
Across 184 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$434
- Lilly USA, LLC$426
- GSK$296
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$283
- Sanofi-aventis U.S. LLC$155
- Teva Pharmaceuticals USA, Inc.$142
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,172100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $434 |
| Lilly USA, LLC | 21 | $426 |
| GSK | 22 | $296 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $283 |
| Sanofi-aventis U.S. LLC | 8 | $155 |
| Teva Pharmaceuticals USA, Inc. | 7 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $140 |
| AstraZeneca | 8 | $139 |
| Merck | 7 | $138 |
| Boehringer Ingelheim | 8 | $137 |
| AbbVie | 5 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $118 |
| Amgen | 6 | $106 |
| Bayer | 5 | $105 |
| Corcept Therapeutics | 3 | $84 |
| Pfizer | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $42 |
| Exact Sciences | 2 | $40 |
| Cequr Corporation | 2 | $38 |
| Abbott | 2 | $33 |
| Heartflow, Inc. | 2 | $31 |
| Optinose US, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$3,186 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $98,378 |
| JardianceEmpagliflozin | 24 | $24,883 |
| EliquisApixaban | 26 | $20,225 |
| JanuviaSitagliptin Phosphate | 24 | $18,287 |
| XareltoRivaroxaban | 12 | $15,755 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,624 |
| FarxigaDapagliflozin Propanediol | 23 | $13,929 |
| MyrbetriqMirabegron | 11 | $6,883 |
| LinzessLinaclotide | 12 | $6,345 |
| SynthroidLevothyroxine Sodium | 29 | $2,396 |
| Atorvastatin Calcium | 228 | $1,909 |
| Levothyroxine Sodium | 195 | $1,688 |
| Omeprazole | 69 | $1,367 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,331 |
| Testosterone | 11 | $1,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $434 | $98,37897 claims |
| Boehringer IngelheimJardiance | $137 | $24,88324 claims |
| PfizerEliquis | $43 | $20,22526 claims |
| MerckJanuvia | $138 | $18,28724 claims |
| Johnson & JohnsonXarelto | $15 | $15,75512 claims |
| GSKTrelegy Ellipta | $296 | $15,62424 claims |
| AstraZenecaFarxiga | $139 | $13,92923 claims |
| AbbVieLinzess, Synthroid | $128 | $8,74141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.
Other family in Southbury
- Michelle HundtSouthbury$12K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.